NEW YORK, March 09, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cenovus Energy Inc (NYSE:CVE), Depomed, Inc. (NASDAQ:DEPO), Zoe's Kitchen, Inc. (NYSE:ZOES), NetApp, Inc. (NASDAQ:NTAP), Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX), and Ocular Therapeutix, Inc. (NASDAQ:OCUL), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
CVE DOWNLOAD: http://Fundamental-Markets.com/register/?so=CVE
DEPO DOWNLOAD: http://Fundamental-Markets.com/register/?so=DEPO
ZOES DOWNLOAD: http://Fundamental-Markets.com/register/?so=ZOES
NTAP DOWNLOAD: http://Fundamental-Markets.com/register/?so=NTAP
KERX DOWNLOAD: http://Fundamental-Markets.com/register/?so=KERX
OCUL DOWNLOAD: http://Fundamental-Markets.com/register/?so=OCUL
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Fundamental Markets, available for free download at the links above, examine Cenovus Energy Inc (NYSE:CVE), Depomed, Inc. (NASDAQ:DEPO), Zoe's Kitchen, Inc. (NYSE:ZOES), NetApp, Inc. (NASDAQ:NTAP), Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX), and Ocular Therapeutix, Inc. (NASDAQ:OCUL) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed March 7th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
CENOVUS ENERGY INC (CVE) REPORT OVERVIEW
Cenovus Energy's Recent Financial Performance
For the three months ended December 31st, 2017 vs December 31st, 2016, Cenovus Energy reported revenue of $3,724.67MM vs $2,709.58MM (up 37.46%) and basic earnings per share $0.45 vs $0.09 (up 404.15%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Cenovus Energy reported revenue of $13,146.97MM vs $9,163.60MM (up 43.47%) and basic earnings per share $2.35 vs -$0.49. Cenovus Energy is expected to report earnings on April 25th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was -$0.04. The estimated EPS forecast for the next fiscal year is $0.53 and is expected to report on February 21st, 2019.
To read the full Cenovus Energy Inc (CVE) report, download it here: http://Fundamental-Markets.com/register/?so=CVE
-----------------------------------------
DEPOMED, INC. (DEPO) REPORT OVERVIEW
Depomed's Recent Financial Performance
For the three months ended December 31st, 2017 vs December 31st, 2016, Depomed reported revenue of $94.41MM vs $123.91MM (down 23.81%) and basic earnings per share -$0.52 vs -$0.73. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Depomed reported revenue of $380.72MM vs $455.90MM (down 16.49%) and basic earnings per share -$1.63 vs -$1.45. Depomed is expected to report earnings on May 8th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was -$0.43. The estimated EPS forecast for the next fiscal year is -$0.40 and is expected to report on February 26th, 2019.
To read the full Depomed, Inc. (DEPO) report, download it here: http://Fundamental-Markets.com/register/?so=DEPO
-----------------------------------------
ZOE'S KITCHEN, INC. (ZOES) REPORT OVERVIEW
Zoe's Kitchen's Recent Financial Performance
For the three months ended December 31st, 2017 vs December 31st, 2016, Zoe's Kitchen reported revenue of $71.38MM vs $61.98MM (up 15.16%) and basic earnings per share -$0.14 vs -$0.02. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Zoe's Kitchen reported revenue of $314.10MM vs $275.96MM (up 13.82%) and basic earnings per share -$0.10 vs $0.09. Zoe's Kitchen is expected to report earnings on May 24th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.01. The estimated EPS forecast for the next fiscal year is -$0.04 and is expected to report on February 28th, 2019.
To read the full Zoe's Kitchen, Inc. (ZOES) report, download it here: http://Fundamental-Markets.com/register/?so=ZOES
-----------------------------------------
NETAPP, INC. (NTAP) REPORT OVERVIEW
NetApp's Recent Financial Performance
For the three months ended January 31st, 2018 vs January 31st, 2017, NetApp reported revenue of $1,523.00MM vs $1,404.00MM (up 8.48%) and basic earnings per share -$1.89 vs $0.53. For the twelve months ended April 30th, 2017 vs April 30th, 2016, NetApp reported revenue of $5,519.00MM vs $5,546.00MM (down 0.49%) and basic earnings per share $1.85 vs $0.78 (up 137.18%). NetApp is expected to report earnings on May 23rd, 2018. The report will be for the fiscal period ending April 30th, 2018. The reported EPS for the same quarter last year was $0.72. The estimated EPS forecast for the next fiscal year is $3.19 and is expected to report on May 23rd, 2018.
To read the full NetApp, Inc. (NTAP) report, download it here: http://Fundamental-Markets.com/register/?so=NTAP
-----------------------------------------
KERYX BIOPHARMACEUTICALS, INC. (KERX) REPORT OVERVIEW
Keryx Biopharmaceuticals' Recent Financial Performance
For the three months ended December 31st, 2017 vs December 31st, 2016, Keryx Biopharmaceuticals reported revenue of $18.68MM vs $9.53MM (up 95.97%) and basic earnings per share -$0.25 vs -$0.32. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Keryx Biopharmaceuticals reported revenue of $60.64MM vs $31.98MM (up 89.60%) and basic earnings per share -$1.43 vs -$1.52. Keryx Biopharmaceuticals is expected to report earnings on May 3rd, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was -$0.21. The estimated EPS forecast for the next fiscal year is -$0.23 and is expected to report on February 6th, 2019.
To read the full Keryx Biopharmaceuticals, Inc. (KERX) report, download it here: http://Fundamental-Markets.com/register/?so=KERX
-----------------------------------------
OCULAR THERAPEUTIX, INC. (OCUL) REPORT OVERVIEW
Ocular Therapeutix's Recent Financial Performance
For the three months ended September 30th, 2017 vs September 30th, 2016, Ocular Therapeutix reported revenue of $0.52MM vs $0.48MM (up 9.64%) and basic earnings per share -$0.54 vs -$0.39. For the twelve months ended December 31st, 2016 vs December 31st, 2015, Ocular Therapeutix reported revenue of $1.89MM vs $1.75MM (up 7.83%) and basic earnings per share -$1.80 vs -$1.71. Ocular Therapeutix is expected to report earnings on March 8th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$0.52. The estimated EPS forecast for the next fiscal year is -$2.22 and is expected to report on March 8th, 2018.
To read the full Ocular Therapeutix, Inc. (OCUL) report, download it here: http://Fundamental-Markets.com/register/?so=OCUL
-----------------------------------------
ABOUT FUNDAMENTAL MARKETS
Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.
REGISTERED MEMBER STATUS
Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.
Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com
© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.